Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Public Citizen: US FDA Deliberately Excluded Risk Committee From Dsuvia Panel To Get Positive Vote

Oct 19 2018

• By Michael Cipriano

Related Content

Trevena's IV Opioid Not Quite 'Ready for Primetime,' US FDA Panel Concludes

Oct 12 2018

Dsuvia's Thumbs Up From US FDA Advisory Panel Is First Positive Vote For An Opioid In 2018

Oct 15 2018

AcelRx's Sublingual Opioid Dsuvia Brings Unique Risk To Advisory Panel: Dropped Tablets

Oct 11 2018

FDA Intellectual Bias Policy Takes Wolfe Off Contraceptives Safety Review

Dec 06 2011

TIRF REMS Debate: Advisory Committee Chair Speaks Out

Aug 29 2018

Related Companies

Talphera, Inc.

Trevena Inc.

Pacira BioSciences, Inc.

Bayer AG

Additional Topics

United States Advisory Committees Drug Review Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.